Anumana Appoints Harry S. Palmin as CFO

CAMBRIDGE, Mass.--()--Anumana, a leading AI-driven health technology company and portfolio company of nference, today announced the appointment of Harry S. Palmin as chief financial officer (CFO). As a veteran in building, financing, and operating life sciences companies, Palmin brings over 25 years of experience to Anumana’s executive leadership team. In his new role, he will lead financial operations, investor relations, and corporate development activities at Anumana, and guide the company’s strategic growth. In addition to his role as CFO of Anumana, Palmin joins nference as CFO, Ventures.

Palmin's distinguished career includes tenure as CFO at Acer Therapeutics Inc., where he played a pivotal role in the company's successful acquisition by Zevra Therapeutics, Inc. His leadership was instrumental in Acer's public offering and the company’s FDA approval for OLPRUVATM, a treatment for urea cycle disorders. Prior to his role at Acer, Palmin served in multiple executive positions at Novelos Therapeutics, Inc., where he helped transform the company from conceptual stage into a leading public oncology and infectious disease development entity.

“Harry is a highly skilled and accomplished executive with a proven track record in building successful companies in the life sciences industry,” said Maulik Nanavaty, CEO of Anumana. “I am thrilled to welcome Harry to Anumana at an exciting time for the company, where we are making tremendous progress in pipeline development and commercial traction. I look forward to partnering with him through our next phase of growth.”

Anumana is at the forefront of revolutionizing healthcare with its groundbreaking ECG-AITM platform that, from standard ECGs at the point of care, enables the identification of hidden cardiovascular diseases for which effective, lifesaving treatments may be available. The ECG-AI platform won the 2024 MedTech Breakthrough Award for “Best New Technology Solution- Cardiology.”

The company’s lead algorithm, ECG-AI LEF, an FDA Breakthrough Device-designated medical device, recently received FDA clearance for detecting low ejection fraction, a common undiagnosed indicator of heart failure1 and prevalent progressive disease that affects over 6 million people in the U.S. and is associated with a significant total annual healthcare cost.2 Anumana’s expansive development pipeline also includes three additional algorithms with FDA Breakthrough Device designation (pulmonary hypertension, cardiac amyloidosis, and hyperkalemia). The company has multiple ongoing partnerships with leading pharmaceutical companies to further develop and commercialize algorithms in its pipeline.3,4 Anumana also spearheaded the effort to bring reimbursement to ECG-AI, receiving approval for two Category III CPT® codes from the American Medical Association in 2022. These codes are now available and designed to facilitate the use, adoption, and potential reimbursement of emerging technologies in clinical workflows.5

“Anumana is one of the most innovative companies in healthcare technology and it is an honor to be joining the organization at such a pivotal time in its growth,” said Palmin. “The progress Anumana has accomplished in just three years since its founding and the potential impact that Anumana’s AI technology platform can make on patient outcomes are inspiring. I am excited to be part of the team and the mission to use pioneering AI technology to unlock the electrical language of the heart and improve patient care.”

Palmin earned a B.A. in economics and business and an M.A. in international economics and finance from the International Business School at Brandeis University. He also studied at the London School of Economics and the Copenhagen Business School.

About Anumana

Anumana is a leading AI-driven health technology company leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never before. The company was founded by nference in collaboration with Mayo Clinic to leverage the clinical and technical expertise of both organizations, to develop innovative ECG-AI technology into a clinically meaningful, medical-grade, and easy-to-use tool for clinicians to advance patient care. Anumana’s software-as-a-medical device (SaMD) ECG-AI solutions aim to detect hidden diseases using standard of care ECG readings, enabling clinicians to enhance and improve care with real-time AI insights.

Anumana’s lead algorithm, ECG-AI™ LEF, is now available in the U.S. To learn more about how the algorithm can help clinicians identify low ejection fraction (LEF) earlier and schedule a demo, visit us at ECG-AI LEF.

Anumana was named one of Fierce MedTech’s Fierce 15 companies for 2022. Follow Anumana at anumana.ai and on LinkedIn and Twitter.

About nference

nference is unlocking the potential of healthcare data with AI, delivering real-world evidence, insights, and solutions informed by the most comprehensive multimodal data across all therapeutic areas. The company’s extensive de-identified, longitudinal data includes decades of clinical notes along with rich patient histories, vitals, lab tests, radiology images, digital pathology, genomics, and electrophysiology waveforms. Our federated data platform, comprising premier healthcare organizations, including Mayo Clinic, Duke Health, Banner Health, Vanderbilt University Medical Center, and Emory Healthcare, enables advanced research and custom AI model development. With unprecedented access to data from over 40 million patient journeys, our partners can accelerate target discovery, optimize clinical trial design, and enhance lifecycle management. Follow nference on LinkedIn. Visit us at www.nference.com.

References

  1. Jaskanwal D Sara, Takumi Toya, Riad Taher, Amir Lerman, Bernard J Gersh, Nandan S Anavekar. Asymptomatic Left Ventricle Systolic Dysfunction. European Cardiology Review 2020, 15:e13; https://doi.org/10.15420/ecr.2019.14.
  2. Khazanie P, Allen LA. Systematizing Heart Failure Population Health. Heart Fail Clin. 2020 Oct;16(4):457-466. doi: 10.1016/j.hfc.2020.06.006. Epub 2020 Jul 21. PMID: 32888640; PMCID: PMC7737815; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737815/.
  3. Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease
  4. Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence
  5. Anumana Announces issuance of New American Medical Association CPT® Category III codes for Novel ECG AI Analysis of Cardiac Dysfunctions

 

Contacts

Sam Choinski
Pazanga Health Communications for Anumana
schoinski@pazangahealth.com
(860) 301-5058

Social Media Profiles

Contacts

Sam Choinski
Pazanga Health Communications for Anumana
schoinski@pazangahealth.com
(860) 301-5058